key: cord-0896527-couvshz9
authors: Villani, Alessia; Costa, Claudia; Fabbrocini, Gabriella; Scalvenzi, Massimiliano
title: Systemic hedgehog inhibitors to treat locally advanced basal cell carcinomas of the head–neck region: A retrospective study
date: 2021-07-01
journal: Dermatol Ther
DOI: 10.1111/dth.15036
sha: 03f7aff130c2649411a620381006897bc7854224
doc_id: 896527
cord_uid: couvshz9

nan

sent advanced BCCs of the head-neck region usually causing functional and cosmetic problems. Standard excision and Mohs surgery are the gold-standard treatment for the majority of BCCs, even if topical treatment, including 5-fluorouracil and imiquimod, photodynamic therapy, cryotherapy, or curettage could also be considered for selected low-risk BCCs. In some they can progress to an advanced stage invading the surrounding structures locally or metastatizing, resulting in locally advanced (la) and metastatic (m) BCCs, respectively.

In the majority of cases, these advanced tumors cause morbidity due to their proximity to critical facial structures resulting in disfigurement and lowering patients' quality of life (QoL) 1,2 Advanced BCCs are not always candidates for surgery or radiation therapy, thus requiring alternative treatments. 3, 4 Sonidegib, is a selective hedgehog pathway inhibitor (HHI) approved in 2015 for patients with laBCC that are ineligible for surgery and/or radiation therapy. 5 To date, clinical trials and case reports regarding its efficacy and tolerability, also during COVID-19 pandemic period, 6 

Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion

Sonidegib: safety and efficacy in treatment of advanced basal cell carcinoma

High-risk recurrence basal cell carcinoma: focus on hedgehog pathway inhibitors and review of the literature

Arsenic trioxide, Itraconazole, all-trans retinoic acid and Nicotinamide: a proof of concept for combined treatments with hedgehog inhibitors in advanced basal cell carcinoma. Biomedicine

Management of locally advanced basal cell carcinoma treated with sonidegib: the experience of an Italian reference hospital

Oral hedgehog pathway inhibition as a means for ocular salvage in locally advanced Intraorbital basal cell carcinoma

Complete remission of an advanced basal cell carcinoma after only 3-month treatment with sonidegib: report of a case and drug management during COVID-19 pandemic

Implementation of systemic hedgehog inhibitors in daily practice as Neoadjuvant therapy

Long-term efficacy of Vismodegib after its withdrawal and Patients' health-related quality of life using the dermatology life quality index (DLQI)